The overexpression of TMEM229A reduces the expression of phosphorylatation levels of ERK, p-ERK, and ERK inhibitor (PD98059) partially suppresses this effect, indicating that the TMEM229A-inhibited tumor progression is partially mediated by inactivating the ERK signaling pathway in NSCLC. Here, TMEM229A is linked to non-small cell lung carcinoma.